Because blocking Gi/o-GPCR signaling suppressed HER2-induced tumor growth, we tested if targeting Gi/o-GPCRs affects the therapeutic efficacy of trastuzumab and lapatinib in Neu, MCF10A/HER2, BT474, and BT474R cells. This evidence concerns the gene ERBB2 and neoplasm.